Blau Farmacêutica Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Blau Farmacêutica wird ein jährliches Gewinn- und Umsatzwachstum von 11.2% bzw. 11.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.1% betragen.

Wichtige Informationen

15.8%

Wachstumsrate der Gewinne

14.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	31.1%
Wachstumsrate der Einnahmen	11.4%
Zukünftige Eigenkapitalrendite	12.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:BLAU3 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (BRL Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,111	301	-39	324	7
12/31/2025	1,880	255	90	337	7
12/31/2024	1,677	203	106	276	7
6/30/2024	1,575	218	2	238	N/A
3/31/2024	1,474	240	20	284	N/A
12/31/2023	1,373	250	-44	221	N/A
9/30/2023	1,352	317	-7	253	N/A
6/30/2023	1,351	312	8	262	N/A
3/31/2023	1,352	354	33	229	N/A
12/31/2022	1,407	363	-8	172	N/A
9/30/2022	1,390	314	104	267	N/A
6/30/2022	1,348	313	96	252	N/A
3/31/2022	1,354	301	-21	137	N/A
12/31/2021	1,366	325	-24	154	N/A
9/30/2021	1,354	354	9	166	N/A
6/30/2021	1,338	335	-13	146	N/A
3/31/2021	1,289	309	13	208	N/A
12/31/2020	1,182	254	53	224	N/A
9/30/2020	1,066	238	-17	183	N/A
6/30/2020	1,029	214	76	245	N/A
3/31/2020	1,008	203	103	217	N/A
12/31/2019	978	200	125	221	N/A
9/30/2019	987	186	72	131	N/A
6/30/2019	938	177	24	82	N/A
3/31/2019	819	129	19	77	N/A
12/31/2018	782	123	32	83	N/A
9/30/2018	677	90	27	67	N/A
6/30/2018	616	78	62	90	N/A
3/31/2018	634	110	N/A	137	N/A
12/31/2017	618	103	N/A	127	N/A
12/31/2016	431	32	N/A	46	N/A
12/31/2015	379	22	N/A	42	N/A
12/31/2014	299	17	N/A	14	N/A
12/31/2013	271	15	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BLAU3Das prognostizierte Gewinnwachstum (11.2% pro Jahr) liegt über der Sparquote (9.9%).

Ertrag vs. Markt: BLAU3Die Erträge des Unternehmens (14.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BR (14.2% pro Jahr).

Hohe Wachstumserträge: BLAU3Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BLAU3Die Einnahmen des Unternehmens (11.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BR (7.2% pro Jahr).

Hohe Wachstumseinnahmen: BLAU3Die Einnahmen des Unternehmens (11.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BLAU3Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.1%).

Blau Farmacêutica Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 9.1% to R$14.29

Price target decreased by 14% to R$15.71

Consensus EPS estimates fall by 14%

Price target decreased by 7.9% to R$19.86

Consensus revenue estimates fall by 16%

Consensus EPS estimates fall by 12%

Recent updates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 15%

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.29 in 1Q 2023)

Price target decreased by 9.1% to R$14.29

Upcoming dividend of R$0.014 per share

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 14% to R$15.71

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 14%

Blau Farmacêutica S.A. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.9% to R$19.86

Consensus revenue estimates fall by 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall by 12%

Blau Farmacêutica S.A. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.4% to R$27.39

Price target decreased by 7.1% to R$29.17

Price target decreased by 7.4% to R$31.40

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Consensus revenue estimates decrease by 12%

Consensus EPS estimates fall by 19%

First quarter 2023 earnings released: EPS: R$0.29 (vs R$0.34 in 1Q 2022)

Price target decreased by 7.7% to R$33.91

Price target decreased by 8.3% to R$34.58

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of R$0.052 per share at 3.0% yield

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Insufficient new directors

Third quarter 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued

Now 22% undervalued

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to R$37.57

Now 21% undervalued after recent price drop

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Second quarter 2021 earnings released: EPS R$0.56 (vs R$0.50 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS R$0.58 (vs R$0.21 in 1Q 2020)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken